Cyclerion Stock Based Compensation vs Capital Expenditures Analysis
| CYCN Stock | USD 6.35 4.74 294.41% |
Cyclerion Therapeutics financial indicator trend analysis is way more than just evaluating Cyclerion Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclerion Therapeutics is a good investment. Please check the relationship between Cyclerion Therapeutics Stock Based Compensation and its Capital Expenditures accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.
Stock Based Compensation vs Capital Expenditures
Stock Based Compensation vs Capital Expenditures Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclerion Therapeutics Stock Based Compensation account and Capital Expenditures. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Cyclerion Therapeutics' Stock Based Compensation and Capital Expenditures is 0.82. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Cyclerion Therapeutics, assuming nothing else is changed. The correlation between historical values of Cyclerion Therapeutics' Stock Based Compensation and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Cyclerion Therapeutics are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Stock Based Compensation i.e., Cyclerion Therapeutics' Stock Based Compensation and Capital Expenditures go up and down completely randomly.
Correlation Coefficient | 0.82 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Capital Expenditures
Capital Expenditures are funds used by Cyclerion Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Cyclerion Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most indicators from Cyclerion Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclerion Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.At this time, Cyclerion Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 4th of December 2024, Sales General And Administrative To Revenue is likely to grow to 46.15, while Issuance Of Capital Stock is likely to drop about 4.3 M.
Cyclerion Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Cyclerion Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cyclerion Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 186.5M | 115.4M | 59.3M | 18.1M | 13.4M | 12.7M | |
| Other Current Liab | 404K | 8.7M | 9.3M | 4.7M | 888K | 843.6K | |
| Total Current Liabilities | 18.2M | 17.0M | 11.1M | 7.6M | 2.1M | 2.0M | |
| Total Stockholder Equity | 97.7M | 59.5M | 48.2M | 10.5M | 11.3M | 10.7M | |
| Net Tangible Assets | 97.7M | 98.4M | 48.2M | 10.5M | 12.0M | 11.4M | |
| Retained Earnings | (85.6M) | (163.4M) | (215.1M) | (259.2M) | (264.4M) | (251.2M) | |
| Accounts Payable | 3.3M | 1.4M | 1.8M | 3.0M | 1.2M | 1.7M | |
| Cash | 94.9M | 54.4M | 54.0M | 13.4M | 7.6M | 7.2M | |
| Other Assets | 5.5M | 50.0M | 2.4M | 2.0M | 2.3M | 2.2M | |
| Inventory | 2.0M | 816K | 928K | 805K | 925.8K | 709.5K | |
| Other Current Assets | 2.9M | 4.0M | 1.4M | 1.3M | 453K | 430.4K | |
| Other Stockholder Equity | 183.4M | 222.9M | 263.3M | 269.6M | 275.7M | 168.8M | |
| Total Liab | 88.7M | 55.9M | 11.1M | 7.6M | 2.1M | 2.0M | |
| Total Current Assets | 101.2M | 58.5M | 55.5M | 14.8M | 8.0M | 7.6M | |
| Accumulated Other Comprehensive Income | (15.5M) | (20K) | (27K) | (23K) | (12K) | (12.6K) | |
| Property Plant Equipment | 79.8M | 6.9M | 1.5M | 1.2M | 1.1M | 1.0M | |
| Property Plant And Equipment Net | 6.5M | 79.8M | 50.3M | 1.5M | 1.2M | 0.0 | |
| Non Current Assets Total | 85.3M | 56.9M | 3.9M | 3.3M | 5.4M | 5.1M | |
| Non Currrent Assets Other | 540K | 2.8M | 2.4M | 2.0M | 5.4M | 5.6M | |
| Common Stock Shares Outstanding | 1.4M | 1.5M | 2.0M | 2.2M | 2.3M | 1.9M | |
| Liabilities And Stockholders Equity | 186.5M | 115.4M | 59.3M | 18.1M | 13.4M | 12.7M | |
| Net Invested Capital | 97.7M | 63.0M | 48.2M | 10.5M | 11.3M | 10.7M | |
| Property Plant And Equipment Gross | 79.8M | 6.9M | 3.7M | 3.4M | 126K | 119.7K | |
| Net Working Capital | 82.9M | 41.5M | 44.4M | 7.2M | 5.9M | 5.6M |
Pair Trading with Cyclerion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Cyclerion Stock
Moving against Cyclerion Stock
| 0.77 | VCYT | Veracyte | PairCorr |
| 0.68 | VCEL | Vericel Corp Ord | PairCorr |
| 0.63 | VERA | Vera Therapeutics | PairCorr |
| 0.49 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.45 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.